Salix Pharmaceuticals — Proxy Contest (June 2003)
37 slides from Salix Pharmaceuticals's proxy contest presentation, Jun 13, 2003
Slide 1: Presentation to Institutional Shareholder Services
Exhibit 99.2 Salix Pharmaceuticals, Ltd. Presentation to Institutional Shareholder Services June 4, 2003 Salix Pharmaceuticals, Ltd.
Slide 2: Why Support the Incumbent Board of Directors?
WHY SUPPORT THE INCUMBENT BOARD OF DIRECTORS? Strong business execution — Salix’s Board has consistently made decisions that have enhanced stockholder value — Salix is at the cusp of realizing the benefit of our efforts and success in executing our business plan — Salix is poised for significant gro
Slide 3: Corporate Profile
CORPORATE PROFILE Specialty pharmaceutical company n Gastroenterology-focused Headquarters: Raleigh, NC 135 employees n 84-member sales and marketing team COLAZAL ® product revenues — 2001 $14.1 million — 2002 $33.5 million — 2003 $53E million — 2004 $70—73E million
Slide 4: Mission Statement
MISSION STATEMENT Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to gastroenterologists and their patients
Slide 5: Salix Has a Clear, Focused Strategy
SALIX HAS A CLEAR, FOCUSED STRATEGY Enhance stockholder value: In-license selective late-stage/marketed product candidates — U.S. gastroenterology focus — Reduce risk and capital commitment Complete any required development and secure FDA approval Sell products through specialty sales force — Establ
Slide 6: Salix Has Successfully Executed Its Business Plan
SALIX HAS SUCCESSFULLY EXECUTED ITS BUSINESS PLAN Premier Specialty Sales Force COLAZAL ® —approved and marketed Rifaximin—FDA approvable letter Granulated mesalamine—scheduled to enter Phase III
Slide 7: Premier Gastroenterology Sales Force
PREMIER GASTROENTEROLOGY SALES FORCE 84-member sales and marketing team Experienced, incentivized professionals Reputation for integrity and quality Established franchise with gastroenterologists Infrastructure in place to be leveraged with future products
Slide 8: COLAZAL
COLAZAL Approved for first-line treatment of mildly to moderately active ulcerative colitis (UC) The fastest growing drug of its kind in the marketplace based upon 2002 prescriptions COLAZAL revenue alone is expected to provide profitability in the second half of 2004
Slide 9: COLAZAL Total Prescriptions
COLAZAL TOTAL PRESCRIPTIONS [GRAPHICS APPEARS HERE] Source: NDC
Slide 10: 5-ASA Market Share Change Since COLAZAL Launch
5-ASA MARKET SHARE CHANGE SINCE COLAZAL LAUNCH [GRAPHICS APPEARS HERE] Source: NDC Health Called-On Physicians
Slide 11: Rifaximin
RIFAXIMIN A unique, broad-spectrum, gastrointestinal-specific, non-absorbed, oral antibiotic FDA approvable letter received October 2002 FDA approvable letter response—4Q/2003 Anticipated launch—mid-2004 Approval in 2004 provides profitability for 2004 Expected to be bigger than COLAZAL with a poten
Slide 12: Rifaximin (Continued)
RIFAXIMIN (CONTINUED) Travelers’ diarrhea—First indication Over 100 clinical publications for a broad range of GI diseases Clinical studies for additional potential uses — Completed n Hepatic encephalopathy, Crohn’s disease — Ongoing n Pouchitis, C. difficile- associated diarrhea — Soon-to-be-initia
Slide 13: Granulated Mesalamine
GRANULATED MESALAMINE In-licensed from Dr. Falk Pharma, a leading European gastroenterology company Given unique release mechanism, Salix intends to develop for: — expanded ulcerative colitis treatment options — improved dosing regimens Patent protected to 2018 First right of negotiation for certain
Slide 14: Salix Is Successfully Executing Its Business Plan
SALIX IS SUCCESSFULLY EXECUTING ITS BUSINESS PLAN Salix has made tremendous progress over three years in building a thriving specialty pharmaceutical franchise Salix has proven its ability to in-license, complete any required development, and launch and sell drugs through our focused specialty sales
Slide 15: Corporate Governance
CORPORATE GOVERNANCE
Slide 16: Salix Is Governed by an Independent Board
SALIX IS GOVERNED BY AN INDEPENDENT BOARD John F. Chappell IO Former Chairman, Worldwide Pharmaceuticals, SmithKline Beecham plc (28 yrs pharmaceutical executive) Thomas W. D’Alonzo IO Former President, PPD, Inc. & Glaxo, Inc. (17 yrs pharmaceutical executive) Richard A. Franco IO Former Chairman an
Slide 17: Key Board Committees Are Fully Independent
KEY BOARD COMMITTEES ARE FULLY INDEPENDENT Audit, Compensation and Nominating Committee members John F. Chappell Chair, Compensation Thomas W. D’Alonzo Chair, Audit Richard A. Franco Chair, Nominating
Slide 18: Salix Board's Interests Are Aligned with Its Stockholders
SALIX BOARD’S INTERESTS ARE ALIGNED WITH ITS STOCKHOLDERS Shares Owned % O.S.** Salix Directors* 1,624,396 7.6 % Axcan (Saule Holdings) 0.0005 % * Salix Officers and Directors hold an aggregate of 3.3 million shares of SLXP common stock, representing 15.5 % of O.S. The aggregate market value of thei
Slide 19: Salix Practices Good Corporate Governance
SALIX PRACTICES GOOD CORPORATE GOVERNANCE All directors elected annually Stockholders can amend the bylaws by majority vote Holders of 10% can call special meetings Merger can be approved by simple majority vote Original Rights Plan approved by stockholders
Slide 20: Salix Practices Good Corporate Governance (Continued)
SALIX PRACTICES GOOD CORPORATE GOVERNANCE (CONTINUED) The CEO and Chairman roles are separated, and have been since 1999 All directors have excellent meeting attendance Non-audit fees consistently lower than audit fees Auditor appointment ratified by stockholders annually Active involvement of outsi
Slide 21: Shareholder Rights Plan
SHAREHOLDER RIGHTS PLAN Approved by shareholders (94% of votes cast) in June 2000 Updated January 2003 after Salix: — Reincorporated from a British Virgin Islands corporation to a Delaware corporation in 2002 — Changed from Toronto Stock Exchange listing to Nasdaq listing in 2000 Plan was not update
Slide 22: Good Corporate Governance in Action
GOOD CORPORATE GOVERNANCE IN ACTION The Salix Board has a record of carefully considering indications of interest and being advised of, understanding and complying with, their fiduciary duties AXCAN Tender Offer Board has met formally 6 times — over 17 hours of meetings/deliberations Sought and util
Slide 23: Salix Has Always Been Willing to Meet with Third Parties
SALIX HAS ALWAYS BEEN WILLING TO MEET WITH THIRD PARTIES AND DISCUSS STRATEGIC ALTERNATIVES CONTACTS WITH AXCAN April 1999—January 2003 During this period, Salix estimates that there were over 30 communications between Salix and Axcan in the form of meetings, telephone calls, letters and substantive
Slide 24: Salix Has Always Been Willing to Meet (Continued)
SALIX HAS ALWAYS BEEN WILLING TO MEET WITH THIRD PARTIES AND DISCUSS STRATEGIC ALTERNATIVES (CONTINUED) CONTACTS WITH AXCAN January 2003—April 2003 January 2003 Salix seeks to postpone meeting scheduled for January 30, 2003 February—March 2003 No communication between Salix and Axcan April 2003 Axca
Slide 25: Board History of Strategic Decisions That Enhance Stockholder Value
THE SALIX BOARD HAS A HISTORY OF MAKING STRATEGIC DECISIONS THAT ENHANCE STOCKHOLDER VALUE Axcan first sought to acquire Salix on Dec. 14, 1999 when SLXP stock was trading on the TSE at US$ 0.12 per share — The Salix Board determined that its stock at that time did not adequately reflect true value
Slide 26: Salix Has Added Significant Stockholder Value
SALIX HAS ADDED SIGNIFICANT STOCKHOLDER VALUE SLXP and AXCA Relative Stock Price Performance Between Axcan’s 12/14/99 Initial Inquiry and one day prior to its 4/10/03 Offer SLXP: 62-fold increase AXCA: 2.7-fold increase Clearly, by successfully implementing its current business plan initiated in 199
Slide 27: Stockholders Will Once Again Be Better Served by Executing the Business Plan
THE SALIX BOARD BELIEVES STOCKHOLDERS WILL ONCE AGAIN BE BETTER SERVED BY EXECUTING THE BUSINESS PLAN Now, 12 months prior to the projected launch of Salix’s second product, Rifaximin, Axcan is once again trying to acquire Salix at a time when Salix is poised for substantial growth, but when its sto
Slide 28: Valuation Considerations
VALUATION CONSIDERATIONS
Slide 29: Peer Group Valuation Shows Salix Is Significantly Undervalued
PEER GROUP VALUATION SHOWS SALIX IS SIGNIFICANTLY UNDERVALUED ENTERPRISE VALUE* / REVENUE Valuation Data Comparable Company(1) 6/2/2003 Price Revenue(2) Enterprise Value/ Revenue(3) LTM 2003E 2004E LTM 2003E 2004E Alkermes $ 13.11 $ 15.5 $ 52.0 $ 67.2 18.9x 17.3x 13.4x Connetics 16.53 51.7 69.2 93.1
Slide 30: Independent Research: Analysts' Comments
INDEPENDENT RESEARCH ANALYSTS’ COMMENTS The following five (5) slides show selected comments from research analysts that cover Salix Pharmaceuticals, Ltd. Salix has retained the investment banking division of Wachovia Securities as its financial advisor in connection with the Axcan hostile tender of
Slide 31: Analysts' Comments: Axcan Tender Offer and Salix Strategic Plan
INDEPENDENT RESEARCH ANALYSTS’ COMMENTS AXCAN TENDER OFFER AND SALIX STRATEGIC PLAN “Axcan has raised its hostile offer for SLXP to $10.50 per share (from $8.75 per share)…We believe that the new bid does not fully reflect the potential of rifaximin…We believe SLXP shareholders could potentially der
Slide 32: Analysts' Comments: Tender Offer and Strategic Plan (Continued)
INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) AXCAN TENDER OFFER AND SALIX STRATEGIC PLAN “We believe SLXP’s current share price does not fully reflect Rifaximin’s intrinsic value potential.” (M Tong—Wachovia 5/14/03) “We believe the Company has sufficient financial flexibility to execute prod
Slide 33: Analysts' Comments: COLAZAL
INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) COLAZAL “The company has raised its forecast for 2003 COLAZAL sales to $53 million from $50 million…Note that as of the week ending 5/2/03, COLAZAL had an annual run rate of almost $58 million…, which could indicate that the company’s expectations
Slide 34: Analysts' Comments: Rifaximin
INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) RIFAXIMIN “We continue to believe that the company will provide the FDA with all necessary data for a Rifaximin approval in mid-2004 and that this will drive company profitability.. We believe this (travelers’ diarrhea) represents the first of seve
Slide 35: Analysts' Comments: Granulated Mesalamine
INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) GRANULATED MESALAMINE “Given the potential for improved dosing (qd or bid vs. current tid administration), we believe peak sales (of granulated mesalamine product) could be $250-300MM—addressing a market of roughly 500,000 adults in the U.S.” (M He
Slide 36: Why Support the Incumbent Board of Directors?
WHY SUPPORT THE INCUMBENT BOARD OF DIRECTORS? Strong business execution — Salix’s Board has consistently made decisions that have enhanced stockholder value — Salix is at the cusp of realizing the benefit of our efforts and success in executing our business plan — Salix is poised for significant gro
Slide 37: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements presented in this overview which are not historical facts are forward looking statements that involve risks and uncertainties that could cause actual results to differ from projected results. Factors that could cause actual results to differ materially include o